Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
about
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaA study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.The pharmacogenetics of imanitib.Personalized medicine and cancer.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Contribution of tumoral and host solute carriers to clinical drug response.CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models.ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitroA multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reactionHuman transporter database: comprehensive knowledge and discovery tools in the human transporter genes.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.OCT1 and imatinib transport in CML: is it clinically relevant?Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients.Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms.Renal Drug Transporters and Drug Interactions.Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.Fine Mapping and Functional Analysis Reveal a Role of SLC22A1 in Acylcarnitine Transport.Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma.
P2860
Q26781539-DC61D01C-5CB6-4E06-890F-438607E4CBC0Q33427392-BB3AF6ED-DAE0-4F29-A37F-04E969F7CBACQ34469295-E934FDDE-8644-48EB-9117-D4565A94971CQ34608577-F6BFBA8E-684F-4038-846C-E494A90D5F7DQ34871636-B062C769-F2C0-44A0-A400-A51CF0A8EDFAQ35708124-2F47B7F0-EF46-4AD2-AC29-086AE3DD3268Q35930616-B8BE4AF5-DEA8-4601-A893-E9040987B5B6Q35946822-534C9897-A7E8-4795-B43F-DDD8154A3481Q35946876-284BD7E3-6D81-45E7-988D-0CC74C7ABAA0Q36229161-D947BE9C-CC7E-432F-A627-DB1B6C4DF015Q37001278-7CA073B7-95F5-49AC-81A2-A052595DDC30Q37140624-BB51A792-0A10-4397-8D38-ABA8EAB777DFQ37144877-DE58275A-8D59-4064-ACBF-383FFDCADD0BQ37591678-489A750C-F864-4B30-A170-CE59EC08BFF5Q37685527-8131D6F4-0A4A-421B-83FF-A6B2E007430BQ37731289-58C0156B-DD9C-42B5-8B32-050F3CBF2F82Q37862942-EBF0A89A-CE55-4336-B898-8575CF5CC20BQ37899883-4A687C37-619C-4770-B10D-338D4842045FQ37939200-1FC81168-7F9E-490D-8192-863DA6CEEAFCQ38112821-C32C5376-BFB3-43FE-A244-7526AB28B9ADQ38243832-07B47420-123F-4F97-8E71-CC217E7A1D22Q38253243-DE3509C0-27CC-4536-82D5-28787356CAFCQ38540022-23591932-3E8F-4B5A-AA8A-C3021A5F2604Q38622785-01B593DA-66D8-462A-BFE7-3D064A590C48Q38826494-7ADF2375-C549-49A4-B25D-85DBD27406DEQ38843265-4CE9EE2F-A6EF-4C0F-9D02-E8C0DF6CEA04Q38848383-27750F8C-20EA-4199-B890-201796310D1DQ38868934-67C84207-640E-4A5E-AB31-A9C8B09897C3Q38899401-3655771E-6319-4689-92FA-B44B9C146DD7Q38902116-666CD72C-54B2-420C-BE59-AAFA1DCEFC0AQ38996487-5E0B493A-4914-480C-8299-1325312EC27BQ39117848-E97DCC67-EC69-4B79-BD9A-AF82CD1C935DQ39140289-57B47633-E443-460F-A9D2-6868588C5BADQ39531941-E39D5BAC-4F39-4F53-BE0E-DAC98AEC8DC4Q41612371-D32EBFB3-B4FC-4B51-A36B-B32E98FD45A9Q43841175-B413C13C-1142-444D-864E-1F72132B9614Q47216949-27D7E6A0-A3F1-4A81-B81E-DC25A065E48CQ47752654-4FA9FFEC-41A2-4615-ADD9-A556600D693DQ47912945-96B1FC7B-AD58-4363-8987-A989AEB86A63Q49473156-479D59C6-1A06-420E-AE1D-7C4C7289B833
P2860
Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Influence of CYP3A5 and drug t ...... hase chronic myeloid leukemia.
@en
Influence of CYP3A5 and drug t ...... hase chronic myeloid leukemia.
@nl
type
label
Influence of CYP3A5 and drug t ...... hase chronic myeloid leukemia.
@en
Influence of CYP3A5 and drug t ...... hase chronic myeloid leukemia.
@nl
prefLabel
Influence of CYP3A5 and drug t ...... hase chronic myeloid leukemia.
@en
Influence of CYP3A5 and drug t ...... hase chronic myeloid leukemia.
@nl
P2093
P2860
P356
P1476
Influence of CYP3A5 and drug t ...... hase chronic myeloid leukemia.
@en
P2093
Hideaki Kagaya
Hirobumi Saitoh
Hiroyuki Tagawa
Kenichi Sawada
Makoto Hirokawa
Masatomo Miura
Naohito Fujishima
Naoto Takahashi
Stuart A Scott
Tomoko Yoshioka
P2860
P2888
P304
P356
10.1038/JHG.2010.98
P577
2010-08-19T00:00:00Z
P6179
1016132311